A
Axonis
Advancing breakthrough drug discoveries to develop first-in-class therapies for currently incurable neurological disorders
About Axonis
Axonis Therapeutics, Inc. is a Boston-based biotechnology company focused on developing innovative treatments for neurological disorders. The company specializes in creating first-in-class and best-in-class medicines that target KCC2, a critical mediator of inhibition within the brain. Axonis leverages breakthrough discoveries from Boston Hospital, Harvard, and Laval University to develop its proprietary KCC2 discovery engine.
Axonis primarily serves patients suffering from neurological conditions such as epilepsy, pain, and other central nervous system (CNS) pathologies. The company's flagship product, AXN 027, is an oral KCC2 potentiator drug designed to fine-tune inhibition in the brain. First-in-human trials for AXN 027 are scheduled to begin in 2024.
The company operates in the highly specialized neuro-focused biotechnology market. Its business model revolves around advancing its proprietary drug candidates through clinical trials and eventually bringing them to market. Axonis has successfully raised $34 million in dilutive seed funding and $8 million in competitive non-dilutive grants to support its mission.
Revenue generation for Axonis will primarily come from the commercialization of its drug candidates, partnerships with larger pharmaceutical companies, and potential licensing agreements. The company is committed to maintaining the integrity and objectivity of its research activities, ensuring that financial conflicts of interest do not bias its scientific endeavors.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2008
- Headquarters
- Boston, United States
- Employees
- 26
- Open positions
- None listed
- Dealroom signal
- 71.5/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Oct 2024 | $115M | $460M | Solasta Ventures · venBio Partners · Perceptive Advisors · MRL Ventures | ↗ |
| GRANTOther financing | Apr 2023 | $130K | — | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for Axonis is 5.5K monthly website visits, down 15.4% over the last three months. Axonis's team grew 4% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed6 investors entered at this stage
National Institute of Neurological Disorders and Stroke
Alexandria Venture Investments
Reeve Foundation
R3 Bio
Civilization Ventures
BoxOne Ventures
Series A7 investors entered at this stage
venBio Partners
Cormorant Asset Management
Solasta Ventures
Perceptive Advisors
MRL Ventures
Sofinnova Investments
Lumira Ventures
Other known investors1 additional known investor
University of Toronto
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Axonis on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Axonis’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.